Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Dupixent | dupilumab | atopic dermatitis | Do not reimburse | Complete | ||
Brineura | cerliponase alfa | Neuronal Ceroid Lipofuscinosis Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | ||
Aermony RespiClick | fluticasone propionate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Arbesda RespiClick | fluticasone propionate / salmeterol xinafoate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Mavenclad | cladribine | Multiple Sclerosis, relapsing-remitting | Reimburse with clinical criteria and/or conditions | Complete | ||
Symtuza | Darunavir/cobicistat/emtricitabine/tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Ozanex | ozenoxacin | Impetigo | Do not reimburse | Complete | ||
Taltz | ixekizumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | ||
Viberzi | eluxadoline | Irritable bowel syndrome with diarrhea | Do not reimburse | Complete |